<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663868</url>
  </required_header>
  <id_info>
    <org_study_id>BUN143201318000 b</org_study_id>
    <nct_id>NCT03663868</nct_id>
  </id_info>
  <brief_title>Single-center Prospective Cumulus Cell Test Study in rFSH Patients</brief_title>
  <official_title>Cumulus Cell mRNA Analysis as Oocyte Quality Marker in the Fertility Lab in a Prospective Single-center Study for rFSH Stimulated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Performing an additional non-invasive oocyte diagnostic test based on cumulus cell gene
      expression could improve the outcome of the ART cycle for rFSH stimulated patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy as observed by ultrasound</measure>
    <time_frame>2 months after embryo transfer</time_frame>
    <description>This observation is routinely performed by the treating physician for every patient undergoing standard ART treatment and is thus available from the fertility center database</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive beta-hCG pregnancy as observed by serum analysis</measure>
    <time_frame>12-17 days after embryo transfer</time_frame>
    <description>This observation is routinely performed by the treating physician for every patient undergoing standard ART treatment and is thus available from the fertility center database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth by questionnaire</measure>
    <time_frame>at least 9 months after embryo transfer</time_frame>
    <description>This observation is routinely performed by the study nurses of the fertility center for every patient undergoing standard ART treatment and is thus available from the fertility center database. This measurement does not include a scale, there is either a child born or not. The date of delivery and the gender of the child are asked together with eventual complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative pregnancy by ultrasound (for pregnancy follow-up) and questionnaire (for live birth follow-up) (see outcome 1 and 3)</measure>
    <time_frame>2 years after embryo transfer</time_frame>
    <description>This is the compilation of the data gathered in outcome 1 and 3 for eventual consecutive cycles. This observation is routinely performed by the study nurses of the fertility center for every patient undergoing standard ART treatment and is thus available from the fertility center database</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>CC-Test diagnosis and Day 3 transfer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Day 3 transfer control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 3 of embryo growth (cleavage stage embryo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Day 5 transfer control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 5 of embryo growth (blastocyst stage embryo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CC-Test</intervention_name>
    <description>Classification of the oocyte/embryo based on the gene expression pattern observed in the cumulus cells</description>
    <arm_group_label>CC-Test diagnosis and Day 3 transfer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  scheduled for intracytoplasmatic sperm injection (ICSI) and single (or double) embryo
             transfer on day 3

          -  patients down regulated with gonadotropin-releasing hormone (GnRH) antagonist and
             stimulated with recombinant Follicle Stimulating Hormone (FSH)

          -  undergoing first or second IVF or ICSI cycle with transfer

          -  Body Mass Index (BMI) between 17 and 33

          -  regular menstrual cycle (between 24 and 35 days)

        Exclusion Criteria:

          -  smokers (&gt; 10 cigarettes per day)

          -  patients requesting Pre-implantation Genetic Diagnosis (PGD)

          -  patients with polycystic ovary syndrome (PCOS), or severe endometriosis (AFS stage
             3-4)

          -  couples where the partner has an extremely low sperm count i.e.: extreme
             oligo-astheno-teratozoospermia (OAT) (&lt; 100.000/ml) or scheduled for testicular sperm
             extraction (TESE)

          -  results of eventual preceding cycles may not indicate a known genetic disease, or low
             ovarian response or an oocyte maturation defect
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Smitz, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inge Van Vaerenbergh, PhD</last_name>
    <phone>+32 2 477 46 45</phone>
    <email>inge.vanvaerenbergh@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom Adriaenssens, MSc</last_name>
    <phone>+32 2 477 46 45</phone>
    <email>tom.adriaenssens@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Van Vaerenbergh, PhD</last_name>
      <phone>+32 2 477 46 45</phone>
      <email>inge.vanvaerenbergh@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Johan Smitz, Prof. Dr.</last_name>
      <phone>+32 2 477 50 52</phone>
      <email>johan.smitz@uzbrussel.be</email>
    </contact_backup>
    <investigator>
      <last_name>Inge Van Vaerenbergh, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Adriaenssens, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>September 14, 2018</last_update_submitted>
  <last_update_submitted_qc>September 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

